We first employed site-specific CCN1 mutations specifically abolishing the receptor-binding sites to either αvβ3/αvβ5 or α6β1 to delineate the integrin partner responsible for CCN1-driven endocrine resistance in breast cancer. Here, CCN1 is linked to breast cancer.